Angus, United Kingdom

David Blake



Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: David Blake: Innovator in Therapeutic Compounds

Introduction

David Blake is a notable inventor based in Angus, GB. He has made significant contributions to the field of therapeutic compounds, holding a total of 2 patents. His work focuses on innovative methods for treating various proliferative and viral disorders.

Latest Patents

David Blake's latest patents include a method for treating proliferative disorders using sapacitabine and seliciclib. This invention outlines a dosing regimen that involves administering these compounds in a structured manner over multiple treatment cycles. The first treatment cycle consists of administering sapacitabine for 3 to 5 consecutive days, followed by an optional administration of seliciclib. The second treatment cycle mirrors the first, ensuring a comprehensive approach to treatment. Additionally, he has developed pyrimidin-4-yl-3, 4-thione compounds, which have therapeutic applications for various disorders, including viral and CNS disorders, as well as diabetes.

Career Highlights

David Blake is currently associated with Cyclacel Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex medical challenges.

Collaborations

David collaborates with esteemed colleagues such as Daniella I Zheleva and Shudong Wang, contributing to a dynamic research environment that fosters innovation.

Conclusion

David Blake's contributions to the field of therapeutic compounds highlight his commitment to advancing medical science. His innovative patents and collaborative efforts position him as a key figure in the development of effective treatments for various disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…